Uzm. Dr.Muhammet Sedat Ofluoğlu

  • İlgi Alanları
  • Nükleer tıp
  • Onkolojik pet ct
  • Tiroid hastalıkları

Eğitim ve Uzmanlık
Akdeniz Üniversitesi Antalya Tıp Fakültesi 
Viyana Üniversitesi Tıp fakültesi ABD ve diploma denklik  İstanbul Üniversitesi CerrahpaşaTıp Fakültesi, Nükleer Tıp ABD. - Uzmanlık

Deneyim
Alman Hastanesi (Taksim, Çamlıca)
Vatan Hastanesi (Aksaray, Kadıköy)
GOP-Taksim eğitim Araştırma Hastanesi
VM-Medikal Park Florya Hastanesi

A. Uluslararası hakemli dergilerde yayımlanan makaleler :

A1. Radiation exposure around patients after administration of 123I-Metaiodobenzylguanidine (MIBG). Sedat Ofluoglu, J. Preitfellner, T. Traub, C. Novotny, B. Füger, E. Havlik, A. Kurtaran. Nuklearmedizin 2002; 41: 221-3.

A2. Radiation Synovectomy with Holmium-166 Ferric Hydroxide - a First Experience. Sedat Ofluoglu, E. Schwameis, H. Zehetgruber, E. Havlik, A. Wanivenhaus, I. Schweeger, K. Weiss, H. Sinzinger, C. Pirich. J Nucl Med. 2002 Nov;43(11):1489-94.

A3. Strahlenexposition in der Umgebung von Patienten nach Gabe eines Radiopharmakons in der nulearmedizinischen Diagnostik. J. Preitfellner, A. Kurtaran, T. Traub, Sedat Ofluoglu, E. Havlik. Strahlenschutz 2000; 8: 13-19.

A4. 111In-DOTA-lanreotide scintigraphy in patients with tumors of the lung. T. Traub, V. Petkov, Sedat Ofluoglu, E. Havlik, P. Angelberger, F. Andraea, E. Halvadjieva, C. Brunner, W. Schima, A. Kurtaran, R. Dudczak, I. Virgolini. JNM 2001; 42: 1309-1315.

A5. Impact of Localization Studies on Feasibility of Minimally Invasive Parathyroidectomy in an Endemic Goiter Region G, Prager, C. Czerny, Sedat Ofluoglu, A. Kurtaran, C. Passler, K. Kaczirek, C. Scheuba, B. Niederle. J Am Coll Surg 2003;196:541–548.

A6. Incidence and predictability of amiodarone-induced thyrotoxicosis and hypothyroidism. Hofmann A, Nawara C, Ofluoglu S, Holzmannhofer J, Strohmer B, Pirich C.Wien Klin Wochenschr. 2008;120(15-16):493-8.

A7. New radiopharmaceuticals for receptor scintigraphy and radionuclide therapy. Virgolini I, Traub T, Leimer M, Novotny C, Pangerl T, Ofluoglu S, Halvadjieva E, Smith-Jones P, Flores J, Li SR, Angelberger P, Havlik E, Andreae F, Raderer M, Kurtaran A, Niederle B, Dudczak R. Q J Nucl Med. 2000 Mar;44(1):50-8. Review.

A8. 13N-ammonia rest/stress PET: folic acid improves global coronary vasoreactivity in coronary artery disease patients with normal or elevated homocysteine levels. Graf S, Nikfardjam M, Khorsand A, Ofluoglu S, Nekolla S, Dudczak R, Maurer G, Kletter K, Huber K, Pirich C. Nuklearmedizin. 2006;45(6):248-53.PMID: 17149493

A9. Should lidocaine be avoided for local anesthesia in radiation synovectomy? Schweeger I, Pirich C, Ofluoglu S, Sinzinger H. Q J Nucl Med Mol Imaging. 2004 Sep;48(3):207-10.PMID: 15499294

A10. Bone lesion detection with carrier-added 99mTc-EDTMP in comparison with 99mTc-DPD. Fueger BJ, Mitterhauser M, Wadsak W, Ofluoglu S, Traub T, Karanikas G, Dudczak R, Pirich C. Nucl Med Commun. 2004 Apr;25(4):361-5.

A11. [Radiation doses deriving from patients treated with (166)Ho-ferric hydroxide]

Preitfellner J, Pirich C, John P, Ofluoglu S, Sinzinger H, Havlik E. Nuklearmedizin. 2003 Dec;42(6):251-4. German.

A12. An unusual visualization of the gallbladder by somatostatin receptor (SSTR) scintigraphy: usefulness of hepatobiliary imaging for differential diagnosis. Kurtaran A, Ofluoglu S, Traub T, Tribl B, Speiser P, Grabenwöger F, Schima W, Dudczak R, Virgolini I. Am J Gastroenterol. 2000 May;95(5):1367-8.

A13. Coronary vasoreactivity in subjects with thyroid autoimmunity and subclinical hypothyroidism before and after supplementation with thyroxine. Traub-Weidinger T, Graf S, Beheshti M, Ofluoglu S, Zettinig G, Khorsand A, Nekolla SG, Kletter K, Dudczak R, Pirich C. Thyroid. 2012 Mar;22(3):245-51. doi: 10.1089/thy.2011.0183. Epub 2012 Jan 10.

B. Uluslararası bilimsel toplantılarda sunulan ve bildiri kitabında (Proceedings) basılan bildiriler :

B1. 111In-DOTA-lanreotide (111In-MAURITIUS) scintigraphy in patients with lung tumors. T. Traub, M. Leimer, A. Kurtaran, Sedat Ofluoglu, E. Havlik, P. Angelberger, M. Raderer, J. Flores, C. Brunner, P. Smith-Jones, R. Dudczak, I. Virgolini. J Nucl Med 1999; 40:98.

B2. Human biodistribution, safety and absorbed dose of 99mTc-P1666 vasoactive intestinal peptide (VIP) receptor scintigraphy. I. Virgolini, T. Traub, Sedat Ofluoglu, A. Kurtaran, M. Raderer, S.R.Li, M. Beck, M. Leimer, P. Angelberger, E. Havlik, R. Dudczak, J. Lister-James. J Nucl Med 1999; 40:244.

B3.111In-DOTA-lanreotide (111In-MAURITIUS): a novel tracer for patients with lung tumours. T. Traub, V. Petkov, C. Brunner, A. Kurtaran, Sedat Ofluoglu, E. Havlik, M. Leimer, P. Angelberger, M. Raderer, R. Dudzcak, I. Virgolini. EJNM 1999; 29: 1036.

B4.Comparative study of 111In-DOTA-lanreotide (LAN), 111In-DTPA-D-Phe-1-octreotide (OCT), 111In-DOTA-Tyr3-octreotide (TOCT) and F-18-PET in neuroendocrine tumor patients. I.Virgolini, A. Kurtaran, P. Smith-Jones, E. Havlik, T. Traub, M. Leimer, Sedat Ofluoglu, F. Andreae, M. Raderer, P. Angelberger, A. Becherer, B. Niederle, K. Kletter, W. Schima, R. Dudczak. EJNM 1999; 26: 1156.

B5. 99mTC-P1666 vasoactive intestinal petide (VIP) receptor scintigraphy: clinical efficacy, biodistribution and safety. I.Virgolin, T. Traub, Sedat Ofluoglu, A. Kurtaran, M. Raderer, M. Beck, M. Leimer, P. Angelberger, S. Li, C. Novotny, E. Havlik, R. Dudczak, J. Lister-James. EJNM 1999; 26: 1154.

B6.Comparative 111In-DOTA-lanreotide (LAN) and 111In-DOTA-Tyr3-octreotide (TOCT) scintigraphy: biodistribution and absorbed dose. E. Halvadjieva, P. Angelberger, F. Andreae, T. Traub, Sedat Ofluoglu, A. Kurtaran, E. Havlik, R. Dudczak, I. Virgolini. EJNM 1999; 26: 1119.

B7. Experimental radiopeptide therapy (ERT) with 90Y-DOTA-Tyr3-DPHE1-octreotide. T. Traub, F. Andreae, P. Angelberger, Sedat Ofluoglu, M. Uffmann, A. Kurtaran, E. Halvadijeva, C. Novotny, R. Dudczak, I. Virgolini. J Nucl Med 2000; 41: 14.

B8. Experimental 90Y-DOTA-Tyr3-DPHE1-octreotide therapy in patients with metastatic tumor disease. T. Traub, F. Andreae, P. Angelberger, M. Raderer, Sedat Ofluoglu, A. Kurtaran, E. Halvadjieva, R. Dudczak, I. Virgolini. EJNM 2000, A 7012.

B9. „Syndrom X-Mechanismen der reduzierten koronaren Flußreserve“ Graf S, Khorsand A, Gwechenberger M, Sedat Ofluoglu, Leitha Th, Kletter K, PirichCh, Schmaljohann J, Porenta G, Zehetgruber M Als Vortrag angenommen an der Jahrestagung der Österreichischen Gesellschaft für Nuklearmedizin, 4. Kongress, Februar 2001, Wien Nuklearmedizin 2001;40:A7.

B10.„Prädiktive Parameter für eine reduzierte koronare Flußreserve bei Patienten mit Angina Pektoris und blanden Koronarien“ Graf S, Khorsand A, Gwechenberger M, Sedat Ofluoglu, Leitha Th, Pirich Ch, Schmaljohann J, Sochor H, Porenta G, Zehetgruber M Als Vortrag angenommen an der Jahrestagung der Österreichischen Gesellschaft für Nuklearmedizin, 4. Kongress, Februar 2001, Wien Nuklearmedizin 2001;40:A8.

B11.„Myokardvitalität: NOGA Mapping im Vergleich mit FDG-PET und Tl-201 “Graf S, Glogar D, Khorsand A, Göngösy M, Pirich Ch, Sedat Ofluoglu, Leitha Th, Schmaljohann J, Sochor H, Porenta G Als Vortrag angenommen an der Jahrestagung der Österreichischen Gesellschaft für Nuklearmedizin, 4. Kongress, Februar 2001, Wien Nuklearmedizin 2001;40:A8.

B12. „Mechanisms of a reduced coronary flow reserve in patients with angina and normal angiogram“ Graf S, Khorsand A, Gwechenberger M, Sedat Ofluoglu, Pirich Ch, Kletter K, Dudczak R, Sochor H, Porenta G, Zehetgruber M Als Poster angenommen an der Society of Nuclear Medicine, 48th Annual Meeting, Juni 2001,Toronto.

B13. „Incidence and mechanisms of a reduced coronary flow reserve in patients with angina and normal angiogram“ Graf S, Khorsand A, Gwechenberger M, Sedat Ofluoglu, Krcal A, Pirich Ch, Kletter K, Sochor H, Porenta G, Zehetgruber M Als Vortrag angenommen am XXIII Annual Congress of the European Society of Cardiology, September 2001, Stockholm. Als Best-Abstract der am European Heart eingereichten österreichischen Abstracts Erhalt des „Byk-Reisestipendiums“ der Österreichischen Kardiologischen Gesellschaft.

B14. Impaired coronary vasoreactivity in subjects with subclinical hypothyreoidism as evidenced by N-13-ammonia rest/stress PET. Pirich C, Sedat Ofluoglu, Graf S, Zettinig G, Traub T, Dobrocemsky G, Nekolla S, Dudczak R, Kletter K. J of Nucl Med. 2002, Vol 43, Iss 5, pp 183.

B15. Impact of dietary supplementation with folic acid on coronary vasoreactivity in subjects with manifested coronary ertery disease as assessed by (13) NH (3) rest/stress PET. Pirich C, Nikfardjam M, Sedat Ofluoglu, Graf S, Nekolla S, Khorsand A, Dudczak R, Kletter K. J Nucl Med. 2002, Vol 43, Iss 5,pp 184.

B16. Incidence and mechanisms of a reduced coronary flow reserve in patients with angina and normal angiogram. Zehetgruber M, Graf S, Khorsand A, Gwechenberger M, Sedat Ofluoglu, Pirich C, Porenta G, Sochor H, Krcal A, Kletter K. European Heart Journal 2001, Vol 22, pp 474-474.

B17. Carbon-11 acetate PET imaging in prostate cancer patients with rising PSA after radical therapy. Prelimerly results. Kurtaran A, Wachter S, Becherer A, Sedat Ofluoglu, Schmaljohann J, Djavan B, Dudczak R, Kletter K. Eur. J. of Nucl. Med. 2001, Vol 28, Iss 8, pp OS 292.

B18 .The Vienna-protocol on repeated low-dose 153Sm-EDTMP therapy induces pain paliation and lesion regression/stabilisation. Sinzinger H, Weiss K, Granegger S, Sedat Ofluoglu, Kratzik CH, Hajek CH. Eur. J. of Nucl. Med. 2001, Vol 28, Iss 8, pp PS477.

B19. Radiation hazard for patients and relatives after pain palliation with 30 mCi 153Sm-EDTMP Sinzinger H, Sedat Ofluoglu, Havlik E, Granegger S. Eur. J. of Nucl. Med. 2001, Vol 28, Iss 8, pp PS483.

B20. Radiation synovectomy with Holmium-166 ferric hydroxide – A first experience. Sedat Ofluoglu, Schwameis E, Havlik E, Wanivenhaus a, Sinzinger H, Pirich C. Eur. J. of Nucl. Med. 2001, Vol 28, Iss 8, pp PS667.

B21. Performing F-18-FDG and C-11-Methionine PET in the follow-up of gliomas after treatment – Are double investigations useful? Asenbaum S, Pirich C, Potzi C, Sedat Ofluoglu, Moameni A, Kletter K. Journal of Nucl. Med. 2001, Vol 42, Iss 5, pp 974.

B22. Distinction between focal noduler hyperplasia (FHN) and liver metastasis by F-18- FDG PET. Kurtaran A, Becherer A, Mueller C, Raderer M, Schmaljohann J, Schima J, Sedat Ofluoglu, Dudczak R, Kletter K, Virgolini I. Journal of Nucl. Med. 2000, Vol 41, Iss 5, pp 1304.

B23. Y-90-DOTA-Tyr3-DPHE1-Oktreotid Therapie bei Patienten mit metastasierter Tumorerkrankung. T. Traub, F. Andreae, P. Angelberger,M. Uffmann, P. M. Raderer, Sedat Ofluoglu, A. Kurtaran, , R. Dudczak, I. Virgolini. Nuklearmedizin 1/2001, V 14.

B24. Bestimmung der Biodistribution und der Biokinetik von Radiopharmazeutika in der Therapie mit einem Ganzkörperzähler. H. Fischer(1,)(2), H. Aiginger(1), S. Granegger(3), E. Havlik(2), S. Ofluoglu(3), C. Pirich(3), H. Sinzinger (3), F. Steger(4) . 2002, Leoben.

B25. Tc-99m, Tc99m-MIBI, Tl-201-Chlorid, In-111-DTPA-D-Phe-1-Oct ve I-123 MIBG Aplikasyonu sonucu hastanın çevresine yaydığı radyasyon dozu. S. Ofluoğlu, J.Preitfellner, E.Havlik, L.Kabasakal ve A.Kurtaran. 5th international congress of nuclear oncology.1-5 mayis 2002, kusadasi.

 

E. Ulusal bilimsel toplantılarda sunulan ve bildiri kitaplarında basılan bildiriler:

E2.Tanısal amaçlı Nükleer Tıp uygulamalarında hastanın çevresine yaydığı radyasyon dozu. Sedat Ofluoglu, J. Preitfellner, B. J. Fueger, T. Traub, C.Novotny, E. Havlik ve A. Kurtaran. 5th international congress of nuclear oncology.1-5 mayis 2002, kusadasi.

E1. ‘Amiodarone ile oluşan tirotoksikoz ve hipotiroidizmin sıklığı ve önceden tahmin edilebilirliği’ Sedat Ofluoğlu, Andrea Hoffman, Johannes Holzmanhofer ve Christian Pirich. 3. Türkiye Tiroid Hastalıkları Kongresi. 18-20 Nisan 2008, Trabzon.

 

F. Diğer yayınlar: Toplantı Metinleri

F1. A novel and promising tracer for patients with lung tumors: 111In-DOTA-lanreotide (111In-MAURITIUS). T. Traub, P. Petkov, C. Brunner, A. Kurtaran, Sedat Ofluoglu, E. Havlik, M. Leimer, P. Angelberger, M. Raderer, F. Andreae, R. Dudczak, I. Virgolini. 2nd International Wörthersee Symposium in Nuclear Medicine, Velden, Austria, May 13-15, 1999.

F2. Clinical application of 111In-pentreotide, 111In-DOTA-lanreotide, and 123I-vasoactive intestinal peptide scintigraphy. T. Traub, Sedat Ofluoglu, M. Uffmann, A. Kurtaran, M. Raderer, J. Flores, R. Dudczak, I. Virgolini. International Symposium of Neuroendocrine Oncology, Biology and Clinical Aspects, Torino, Italy, March, 22nd-24th, 1999.

F3. Lenfödem kliniğimizde takipli en küçük hasta. Evrim Coşkun Çelik, Sedat Ofluoğlu, Gül Tuğba Bulut, Adem İşi, Ebru Polat. 1. Lenfödem Sempozyumu 30 Eylul-1 Ekim 2016. Anadolu lenfödem Derneği.